Vera Therapeutics, Inc.
VERAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The $2.04B market capitalization puts VERA squarely in mid-cap range for its industry. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Market Cap
$2.04B
Beta
1.05
P/E (TTM)
—
P/E (Fwd)
-6.66
EPS (TTM)
$-5.87
EPS (Fwd)
$-4.25
ROE
-91.8%
ROA
-46.8%
Cash
$499.2M
Total Debt
$76.9M
Free CF
-$212.9M
52W Change
-6.9%
Annual Financials
Cash vs Debt
Where VERA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, VERA finished 22.19% below its 150-day moving average ($35.83) and 26.40% below its 200-day moving average ($37.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VERA overbought or oversold?
At the October 19, 2026 close, VERA's RSI(14) was 27.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $499.2M in cash and $76.9M in debt, VERA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$212.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -91.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VERA.